A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes
Diabetes Mellitus Type 2

About this trial
This is an interventional treatment trial for Diabetes Mellitus Type 2
Eligibility Criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- Diagnosed with type-2 diabetes mellitus with HbA1c ≥6.5% to less than 10.0%
- Body mass index 30.0 to 50.0
Exclusion Criteria:
- Any significant acute or chronic medical illness
- Inability to self-administer subcutaneous injections
- Inability to be venipunctured
- Evidence of organ dysfunction beyond what is consistent with the target population
- History of allergy to PEGylated compounds or Fibroblast growth factor 21 (FGF21) related compounds
Sites / Locations
- Arkansas Clinical Research
- Anaheim Clinical Trials Llc
- National Research Institute
- Encompass Clinical Research
- Encompass Clinical Research
- All Medical Research, Llc
- Central Kentucky Research Associates, Inc.
- Premier Research
- Metrolina Internal Medicine
- Sterling Research Grp, Ltd.
- Manna Research Vancouver
- Aggarwal And Associates
- Rhodin Recherche Clinique
- Recherche Gcp Research
- Medexa Recherche
- Alpha-Recherche Clinique
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Placebo Comparator
Experimental
Experimental
Experimental
Experimental
Treatment A: Placebo (Matching with BMS-986036 - Daily)
Arm 2: Treatment B: BMS-986036 (1 mg Daily)
Treatment C: BMS-986036 (5 mg Daily)
Treatment D: BMS-986036 (20 mg Daily)
Treatment E: BMS-986036 (20 mg Weekly)
Placebo (Matching with BMS-986036) 0 mg subcutaneous injection once daily for 12 weeks
BMS-986036 1 mg subcutaneous injection once daily for 12 weeks
BMS-986036 5 mg subcutaneous injection once daily for 12 weeks
BMS-986036 20 mg subcutaneous injection once daily for 12 weeks
BMS-986036 20 mg subcutaneous injection once weekly (on Day 1 of each week) for 12 weeks Followed by Placebo (Matching with BMS-986036) 0 mg subcutaneous injection on Days 2-7 of each week for 12 weeks